General Information of Drug Therapeutic Target (DTT) (ID: TTI2S1D)

DTT Name Cytotoxic T-lymphocyte protein 4 (CTLA-4)
Synonyms Cytotoxic T-lymphocyte-associated antigen 4; CTLA-4; CD152
Gene Name CTLA4
DTT Type
Successful target
[1]
BioChemical Class
Immunoglobulin
UniProt ID
CTLA4_HUMAN
TTD ID
T15000
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MACLGFQRHKAQLNLATRTWPCTLLFFLLFIPVFCKAMHVAQPAVVLASSRGIASFVCEY
ASPGKATEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLR
AMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPEPCPDSDFLLWILAAVSSGLFFYSFL
LTAVSLSKMLKKRSPLTTGVYVKMPPTEPECEKQFQPYFIPIN
Function
Inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28.
KEGG Pathway
Cell adhesion molecules (CAMs) (hsa04514 )
T cell receptor signaling pathway (hsa04660 )
Autoimmune thyroid disease (hsa05320 )
Rheumatoid arthritis (hsa05323 )
Reactome Pathway
CTLA4 inhibitory signaling (R-HSA-389513 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
2 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ipilimumab DMJTIYK Melanoma 2C30 Approved [1]
Tremelimumab DMOQ9H1 Hepatocellular carcinoma 2C12.02 Approved [2]
------------------------------------------------------------------------------------
21 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
AK04 DMU7K86 Actinic keratosis EK90.0 Phase 3 [3]
KN046 DMSDBPG Non-small-cell lung cancer 2C25.Y Phase 3 [4]
AK104 DMXJ8Z4 Cervical cancer 2C77.0 Phase 2 [5]
Lorigerlimab DM2E8Z5 Prostate cancer 2C82.0 Phase 2 [6]
Vudalimab DMSEEI0 Prostate cancer 2C82.0 Phase 2 [7]
AGEN1884 DMAP5B4 Cervical cancer 2C77.0 Phase 1/2 [8]
BMS-986288 DMM10J4 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [9]
MK-1308 DM25QKC Solid tumour/cancer 2A00-2F9Z Phase 1/2 [10]
Zalifrelimab DMNNYAE Cervical cancer 2C77.0 Phase 1/2 [11]
A337 DMXWFP2 Aggressive cancer 2A00-2F9Z Phase 1 [12]
ADG116 DMEXT97 Solid tumour/cancer 2A00-2F9Z Phase 1 [13]
AGEN1181 DMV6JFK Solid tumour/cancer 2A00-2F9Z Phase 1 [14]
ALPN-202 DMTD4EF Solid tumour/cancer 2A00-2F9Z Phase 1 [15]
BMS-986249 DMHTEZ8 Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
MEDI5752 DMJ1E24 Non-small-cell lung cancer 2C25 Phase 1 [16]
MGD019 DM2BYWI Solid tumour/cancer 2A00-2F9Z Phase 1 [17]
ONC-392 DM8B40M Non-small-cell lung cancer 2C25.Y Phase 1 [18]
SI-B003 DMJW5R0 Solid tumour/cancer 2A00-2F9Z Phase 1 [19]
XmAb20717 DMJIH83 Advanced malignancy 2A00-2F9Z Phase 1 [20]
XmAb22841 DMQB3HD Solid tumour/cancer 2A00-2F9Z Phase 1 [21]
YH001 DMHQNVR Aggressive cancer 2A00-2F9Z Phase 1 [22]
------------------------------------------------------------------------------------
⏷ Show the Full List of 21 Clinical Trial Drug(s)
7 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Alpha-D-Mannose DMF5DLW Discovery agent N.A. Investigative [23]
Concatameric CTLA4Ig DMC5RKY Discovery agent N.A. Investigative [2]
CTLA-4-XTEN DMKEIAS Rheumatoid arthritis FA20 Investigative [2]
Del 60 tetramer DMGZ2H5 Solid tumour/cancer 2A00-2F9Z Investigative [24]
Fucose DMAHMSV N. A. N. A. Investigative [23]
GX-C4 DM8GFJP Autoimmune diabetes 5A10 Investigative [2]
YH006 DMRECC2 Aggressive cancer 2A00-2F9Z Investigative [25]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Investigative Drug(s)

Molecular Expression Atlas (MEA) of This DTT

Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This DTT
Disease Name ICD 11 Studied Tissue p-value Fold-Change Z-score
Prostate cancer 2C82 Prostate 2.73E-01 0.02 0.05
Rheumatoid arthritis FA20 Synovial tissue 4.05E-03 -0.21 -1.52
------------------------------------------------------------------------------------

References

1 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2743).
3 A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study). Lung Cancer. 2023 Oct;184:107355.
4 Clinical pipeline report, company report or official report of Alphamab Oncology.
5 Clinical pipeline report, company report or official report of Akeso Biopharma.
6 Clinical pipeline report, company report or official report of MacroGenics
7 Clinical pipeline report, company report or official report of Xencor
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Clinical pipeline report, company report or official report of CytomX Therapeutics.
10 Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol. 2021 Mar;32(3):395-403.
11 Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study. J Clin Oncol. 2022 Mar 1;40(7):762-771.
12 Clinical pipeline report, company report or official report of Klus Pharma
13 Clinical pipeline report, company report or official report of Adagene.
14 Clinical pipeline report, company report or official report of Agenus.
15 Clinical pipeline report, company report or official report of Alpine Immune Sciences.
16 Bispecific Antibodies to PD-1 and CTLA4: Doubling Down on T Cells to Decouple Efficacy from Toxicity. Cancer Discov. 2021 May;11(5):1008-1010.
17 Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule. Cell Rep Med. 2020 Dec 22;1(9):100163.
18 Clinical pipeline report, company report or official report of OncoImmune.
19 Clinical pipeline report, company report or official report of SystImmune.
20 Clinical pipeline report, company report or official report of Xencor.
21 Clinical pipeline report, company report or official report of Xencor.
22 Clinical pipeline report, company report or official report of Biocytogen
23 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
24 Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60.
25 Clinical pipeline report, company report or official report of Biocytogen